Scientists from The Scripps Research Institute have identified a novel synthetic compound that sharply inhibits the activity of a protein that plays an important role in in the progression of breast and pancreatic cancers. In the new study the scientists showed that the compound, known as SR1848, reduces the activity and expression of the cancer-related protein called “liver receptor homolog-1” or LRH-1.
IBM has engineered a way for everyone to join the fight against Ebola—by donating processing...
Researchers can now explore viruses, bacteria and components of the human body in more detail...
Scientists at The Scripps Research Institute have identified weak spots on the surface of Ebola virus that are targeted by the antibodies in ZMapp, the experimental drug cocktail administered to several patients during the recent Ebola outbreak. The study provides a revealing 3-D picture of how the ZMapp antibodies bind to Ebola virus.
Chemists at The Scripps Research Institute and the Shanghai Institute of Organic Chemistry have described a method for creating and modifying organic compounds that overcomes a major limitation of previous methods. The advance opens up a large number of novel chemical structures for synthesis and evaluation, for example, as candidate pharmaceuticals.
A new study by scientists from The Scripps Research Institute, Lawrence Berkeley National Laboratory and other institutions suggests a cause of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The team's work supports a common theme whereby loss of protein stability leads to disease.
Scientists at The Scripps Research Institute have devised a new antibiotic based on vancomycin that is powerfully effective against vancomycin-resistant strains of MRSA and other disease-causing bacteria. The new vancomycin analog appears to have not one but two distinct mechanisms of anti-microbial action, against which bacteria probably cannot evolve resistance quickly.
Scientists from The Scripps Research Institute have discovered a surprising new role for a pair of compounds—which have the potential to alter circadian rhythm, the complex physiological process that responds to a cycle of light and dark and is present in most living things. At least one of these compounds could be developed as a chemical probe to uncover new therapeutic approaches to a range of disorders, including diabetes and obesity.
Scientists working to make gene therapy a reality have solved a major hurdle: how to bypass a blood stem cell’s natural defenses and efficiently insert disease-fighting genes into the cell’s genome. In a new study, a team of researchers report that the drug rapamycin, which is commonly used to slow cancer growth, enables delivery of a therapeutic dose of genes to blood stem cells while preserving stem cell function.
Chemists at The Scripps Research Institute have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration for clinical trials in cancer patients. The new report, published in Angewandte Chemie, focuses on a compound called TIC10.
Scientists have known that abnormal brain growth is associated with autism spectrum disorder. However, the relationship between the two has not been well understood. Now, scientists have shown that mutations in a specific gene that is disrupted in some individuals with autism results in too much growth throughout the brain.
A team led by scientists at The Scripps Research Institute working with the International AIDS Vaccine Initiative has discovered a new vulnerable site on the HIV virus. The newly identified site can be attacked by human antibodies in a way that neutralizes the infectivity of a wide variety of HIV strains.
Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction, a “cytokine storm”, that can both sicken and kill patients who are infected with certain strains of flu virus. Their findingsalso clarify the workings of a potent new class of anti-inflammatory compounds that prevent this immune overreaction in animal models.
Scientists at The Scripps Research Institute have demonstrated the power of a new drug discovery technique, which allows them to find, relatively quickly and cheaply, antibodies that have a desired effect on cells. The TSRI scientists used the technique to discover two antibodies that protect human cells from a cold virus.
Scientists from the Florida campus of The Scripps Research Institute have described a pair of drug candidates that advance the search for new treatments for pain, addiction and other disorders. The two new drug scaffolds offer researchers novel tools that act on a demonstrated therapeutic target, the kappa opioid receptor (KOR), which is located on nerve cells and plays a role in the release of the neurotransmitter dopamine.
Scientists have discovered how the element sodium influences the signaling of a major class of brain cell receptors, known as opioid receptors. The discovery, from The Scripps Research Institute and the Univ. of North Carolina, suggests new therapeutic approaches to a host of brain-related medical conditions.
Lawrence Berkeley National Laboratory researchers at the Advanced Light Source (ALS) have invented a new technique for studying the process by which certain errors in the genetic code are detected and repaired. The technique is based on a combination of hybrid nanomaterials and SAXS imaging at the ALS SIBYLS beamline.
Chemists at The Scripps Research Institute have devised a new technique for connecting drug molecules to antibodies to make advanced therapies. Antibody-drug conjugates are the basis of new therapies on the market that use the target-recognizing ability of antibodies to deliver drug payloads to specific cell types. The new technique allows drug developers to forge more stable conjugates than are possible with current methods.
Researchers at The Scripps Research Institute discovered that an antibody that binds and neutralizes HIV likely also targets the body’s own “self” proteins. This finding could complicate the development of HIV vaccines designed to elicit this protective antibody, called 4E10, and others like it, as doing so might be dangerous or inefficient.
Scientists at The Scripps Research Institute have devised a powerful new technique for finding antibodies that have a desired biological effect. Antibodies, which can bind to billions of distinct targets, are already used in many of the world’s best-selling medicines, diagnostics, and laboratory reagents. The newly reported technique should greatly speed the process of discovering such products.
Scientists at The Scripps Research Institute (TSRI) have illuminated the mechanism at the heart of one of the most useful processes in modern chemistry. A reaction that is robust and easy to perform, it is widely employed to synthesize new pharmaceuticals, biological probes, new materials, and other products. But precisely how it works had been unclear since its invention at TSRI more than a decade ago.
Scientists at The Scripps Research Institute have shown how to synthesize in the laboratory an important set of natural compounds known as terpenes. The largest class of chemicals made by living organisms, terpenes are made within cells by some of the most complex chemical reactions found in biology.
Scientists at The Scripps Research Institute in California and the Technion–Israel Institute of Technology have developed a "biological computer" made entirely from biomolecules that is capable of deciphering images encrypted on DNA chips. Although DNA has been used for encryption in the past, this is the first experimental demonstration of a molecular cryptosystem of images based on DNA computing.
Scientists from the Florida campus of The Scripps Research Institute have identified a compound that can help repair a specific type of defect in RNA. The methods in the new study could accelerate the development of therapeutics to treat a variety of incurable diseases such as Huntington's disease, spinocerebellar ataxia, and Kennedy disease.
Scientists from The Scripps Research Institute have identified a class of compounds that could be a boon to basic research and drug discovery. In a new study, the researchers show the new compounds powerfully and selectively block the activity of a large and diverse group of enzymes known as "serine hydrolases."
An international team of researchers led by scientists at Scripps Institution of Oceanography at UC San Diego has deciphered the genome of a tropical marine organism known to produce substances potentially useful against human diseases.
A scientist from the Florida campus of The Scripps Research Institute has devised a new method of analyzing and quantifying changes in proteins that result from a common chemical process. The new findings could provide new insights into the effects of a highly destructive form of stress on proteins in various disease models, particularly cancer.
Deepwater offshore oil well exploration relies on the collection of electromagnetic signals. The QMax EM3 Receiver (QMax) from Quasar Geophysical Technologies and Scripps Institution of Oceanography uses a new electrode design that overcomes problems with previous receivers.